SVB Leerink analyst Mani Foroohar maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and lowers the price target from $66 to $64.
What 9 Analyst Ratings Have To Say About Delta Air Lines
Analysts have provided the following ratings for Delta Air Lines (NYSE:DAL) within the last quarter: